On October 7, Direxion Daily S&P Biotech Bull 3x Shares fell 11.07% in regular trading, trading at $228.895/share, with Turnover of $198 million.

The decline reflects mounting pressure across the biotechnology sector as renewed concerns over U.S. interest rate expectations weigh on high-duration, zero-revenue biotech companies. The triple-leveraged structure of the ETF amplified losses relative to the underlying S&P Biotechnology Select Industry Index, which itself experienced a modest pullback of 0.06% on the day.

The fund invests at least 80% of its net assets in financial instruments and securities that provide daily leveraged exposure to the index, which is designed to measure the performance of the biotechnology sub-industry based on the Global Industry Classification Standards. The non-diversified nature of the fund further concentrates its sensitivity to sector-wide moves.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)